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Abstract
Each unit of the D4Z4 macrosatellite repeat contains a retrotransposed gene encoding the DUX4 double-homeobox
transcription factor. Facioscapulohumeral dystrophy (FSHD) is caused by deletion of a subset of the D4Z4 units in the
subtelomeric region of chromosome 4. Although it has been reported that the deletion of D4Z4 units induces the
pathological expression of DUX4 mRNA, the association of DUX4 mRNA expression with FSHD has not been rigorously
investigated, nor has any human tissue been identified that normally expresses DUX4 mRNA or protein. We show that FSHD
muscle expresses a different splice form of DUX4 mRNA compared to control muscle. Control muscle produces low amounts
of a splice form of DUX4 encoding only the amino-terminal portion of DUX4. FSHD muscle produces low amounts of a
DUX4 mRNA that encodes the full-length DUX4 protein. The low abundance of full-length DUX4 mRNA in FSHD muscle cells
represents a small subset of nuclei producing a relatively high abundance of DUX4 mRNA and protein. In contrast to control
skeletal muscle and most other somatic tissues, full-length DUX4 transcript and protein is expressed at relatively abundant
levels in human testis, most likely in the germ-line cells. Induced pluripotent (iPS) cells also express full-length DUX4 and
differentiation of control iPS cells to embryoid bodies suppresses expression of full-length DUX4, whereas expression of full-
length DUX4 persists in differentiated FSHD iPS cells. Together, these findings indicate that full-length DUX4 is normally
expressed at specific developmental stages and is suppressed in most somatic tissues. The contraction of the D4Z4 repeat in
FSHD results in a less efficient suppression of the full-length DUX4 mRNA in skeletal muscle cells. Therefore, FSHD
represents the first human disease to be associated with the incomplete developmental silencing of a retrogene array
normally expressed early in development.
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Introduction
Facioscapulohumeral dystrophy (FSHD) is an autosomal
dominant muscular dystrophy caused by the deletion of a subset
of D4Z4 macrosatellite repeat units in the subtelomeric region of
4q on the 4A161 haplotype (FSHD1; OMIM 158900) [1]. The
unaffected population has 11–100 D4Z4 repeat units, whereas
FSHD1 is associated with 1–10 units [2]. The retention of at least
a portion of the D4Z4 macrosatellite in FSHD1 and the
demonstration that the smaller repeat arrays have diminished
markings of heterochromatin [3] support the hypothesis that
repeat contraction results in diminished heterochromatin-mediat-
ed repression of a D4Z4 transcript, or a transcript from the
adjacent subtelomeric region. The hypothesis that derepression of
a regional transcript causes FSHD is further supported by
individuals with the same clinical phenotype and decreased
D4Z4 heterochromatin markings but without a contraction of
the D4Z4 macrosatellite in the pathogenic range (FSHD2) [4,5].
The D4Z4 repeat unit contains a conserved open reading frame
for the DUX4 retrogene, which Clapp et al suggest originated
from the retrotransposition of the DUXC mRNA [6], a gene
present in many mammals but lost in the primate lineage. Dixit
et al [7] demonstrated that DUX4 transcripts were present in
cultured FSHD muscle cells and mapped a polyadenylation site to
the region telomeric to the last repeat, a region referred to as
pLAM. Lemmers et al [8] recently demonstrated that the region
necessary for a contracted D4Z4 array to be pathogenic maps to
this polyadenylation site, which is intact on the permissive 4A
chromosome but not on the non-permissive chromosomes 4B or
10, indicating that stabilization of the DUX4 mRNA is necessary
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demonstrated bidirectional transcription of the D4Z4 region
associated with the generation of small RNAs, and we suggested
that these D4Z4-associated small RNAs might contribute to the
epigenetic silencing of D4Z4. We also identified alternatively
spliced transcripts from the DUX4 retrogene that terminate at the
previously described [7] polyadenylation site in the pLAM region.
However, we identified DUX4 mRNA transcripts in both FSHD
and wild-type muscle cells, as well as similar amounts of D4Z4-
generated small RNAs.
Together these studies implicate a stabilized DUX4 mRNA
transcript from the contracted D4Z4 array as the cause of FSHD.
However, several important questions remain to be addressed:
(1) Our prior study identified two alternative splice forms of the
DUX4 mRNA, which in this report we call DUX4-fl and
DUX4-s, and showed that both control and FSHD muscle
with a 4A chromosome contained polyadenylated DUX4
mRNA. Therefore, it is important to determine whether the
overall abundance of the DUX4 mRNA or the relative
abundance of the alternative splice forms is associated with
FSHD.
(2) All studies reporting DUX4 mRNA associated with FSHD
have used high cycle PCR to detect mRNA that are present at
extremely low abundance. It remains to be determined
whether the amount of DUX4 mRNA detected in FSHD
cells makes sufficient DUX4 protein to have a biological
consequence.
(3) DUX4 has been referred to as a pseudogene and the D4Z4
region has been referred to as ‘‘junk’’ DNA. The conclusion
that DUX4 is not a functional gene is supported only by the
absence of evidence that the DUX4 mRNA and protein is
normally expressed in any human tissue. Yet, the open
reading frame (ORF) of DUX4 is conserved, raising the
possibility that it might have an as yet undetected role in
human biology.
In this study, we address each of these important questions.
Together, our data substantiate a developmental model for FSHD:
full-length DUX4 mRNA is normally expressed early in
development and is suppressed during cellular differentiation,
whereas FSHD is associated with the failure to maintain complete
suppression of full-length DUX4 expression in differentiated
skeletal muscle cells. Occasional escape from repression results in
the expression of relatively large amounts of DUX4 protein in a
small number of skeletal muscle nuclei.
Results
Alternative DUX4 mRNA splicing distinguishes control
and FSHD muscle
A recent study [8] demonstrated that the sequence polymor-
phisms of the 4A161 haplotype necessary for FSHD include the
region of the poly-adenylation signal for the DUX4 mRNA and
showed that this correlated with the detection of DUX4 mRNA in
three FSHD muscle cultures compared to controls. Our previous
study of RNA transcripts from D4Z4 repeat units identified a full-
length mRNA transcript that contains the entire DUX4 open
reading frame and has one or two introns spliced in the 3-prime
UTR (GenBank HQ266760 and HQ266761), and a second
mRNA transcript utilizing a cryptic splice donor in the DUX4
ORF that maintains the amino-terminal double-homeobox
domains and removes the carboxyterminal end of DUX4
(GenBank HQ266762) (Figure 1A and 1B). We will refer to these
two transcripts as DUX4-fl (full length) and DUX4-s (shorter
ORF), respectively (see [9] for splice junction sequences). The
PCR approach in the Lemmers et al study [8] would not have
detected the DUX4-s mRNA.
We used oligo-dT primed cDNA and a PCR strategy that
would detect both DUX4-fl and DUX4-s (see Figure 1B) to
determine the presence of polyadenylated DUX4 mRNAs in
quadriceps muscle needle biopsies from ten FSHD and fifteen
control individuals (Table 1 and Figure 1C). In general we used
two cycles of PCR with nested primers to increase specificity and
to detect low abundance transcripts. DUX4-fl was detected in five
of the ten FSHD samples, based on primers amplifying DUX4-fl
and primers amplifying the 3-prime region of DUX4-fl (DUX4-
fl39) that is contained in DUX4-fl but not in DUX4-s (see
Figure 1B). The sequenced products matched the FSHD-
permissive 4A161 haplotype polymorphisms and the variation in
size of the PCR product reflected alternative splicing of only the
second intron in the UTR or both the first and second UTR
introns (see Figure 1B). In contrast, none of the fifteen control
samples expressed mRNA that amplified with primers to DUX4-fl
or DUX4-fl39, including seven biopsies from individuals with at
least one 4A161 chromosome. Instead, DUX4-s was detected in
all control samples with 4A161 and in some of the FSHD samples.
We did not detect DUX4 transcripts using these primers in six
control biopsies that do not contain the 4A chromosome. These
data indicate that the 4A D4Z4 region is actively transcribed and
produces alternatively spliced and polyadenylated DUX4 mRNA
in both FSHD and unaffected individuals. However, the full-
length DUX4 mRNA was only detected in the FSHD muscle
biopsies, whereas DUX4-s was detected in muscle from controls
and some FSHD individuals.
The expression of DUX4-fl mRNA in FSHD muscle biopsies
could be a primary consequence of the D4Z4 contraction or a
secondary response to the inflammation associated with muscle
degeneration and/or regeneration. Therefore, we extended our
analysis to myoblast cultures derived from four control and six
FSHD individuals, including one individual with FSHD2. As seen
in the muscle biopsies, the control muscle cells contained no
detectable amounts of DUX4-fl mRNA, whereas muscle cells
Author Summary
Facioscapulohumeral muscular dystrophy is caused by the
deletion of a subset of D4Z4 macrosatellite repeats on
chromosome 4. Each repeat contains a retrogene encoding
the double-homeobox factor DUX4. We show that this
retrogene is normally expressed in human testis, most likely
the germ-line cells, and pluripotent stem cells. DUX4
expression is epigenetically suppressed in differentiated
tissues and the residual DUX4 transcripts are spliced to
remove the carboxyterminal domain that has been
associated with cell toxicity. In FSHD individuals, the
expression of the full-length DUX4 transcript is not
completely suppressed in skeletal muscle, and possibly
other differentiated tissues, and results in a small percent-
age of cells expressing relatively abundant amounts of the
full-length DUX4 mRNA and protein. We therefore propose
that FSHD is caused by the inefficient developmental
suppression of the DUX4 retrogene and that the residual
expression of the full-length DUX4 in skeletal muscle is
sufficient to cause the disease. Therefore, FSHD represents
the first human disease to be associated with the
incomplete developmental silencing of a retrogene array
that is normally expressed early in development.
Incomplete Developmental Suppression of DUX4
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fl transcripts as well as the DUX4fl-39 (Table 2 and Figure 1D). All
control and a subset of the FSHD samples expressed DUX4-s.
These data are consistent with observations made in the muscle
biopsies and indicate that both FSHD and control muscle cells
actively transcribe DUX4. Unaffected cells produce DUX4-s from
a splice donor site in the DUX4 ORF, whereas FSHD cells
produce DUX4-fl with an alternative splice donor site after the
translation termination codon of the DUX4 ORF.
A small fraction of FSHD muscle cells produce a relatively
large amount of DUX4
In both control and FSHD cells the DUX4 mRNA transcripts,
either DUX4-fl or DUX4-s, were only detected after nested PCR
amplifications, indicating very low abundance of DUX4 mRNA in
the FSHD and control biopsies and cells. We used the 9A12
mouse monoclonal anti-DUX4 antibody [7] and also produced
mouse and rabbit monoclonal antibodies to the amino-terminal
and carboxyterminal portion of the DUX4 protein [10], but were
unable to detect DUX4 protein in western analysis of FSHD
muscle cultures, consistent with the very low amounts of DUX4
mRNA.
Low transcript abundance could reflect a small number of
transcripts in every cell or a large number of transcripts in a small
subset of cells in the population. We assessed the presence of
DUX4-fl mRNA in samplings of 100, 600, and 10,000 FSHD
cultured muscle cells. DUX4-fl mRNA was present in five-out-of-
ten pools of 600 cells (Figure 2A) and three-out-of-20 pools of 100
cells (data not shown), as well as in the single pool of 10,000 cells.
This frequency of positive pools indicates that approximately one-
out-of-1000 cells is expressing a relatively abundant amount of
DUX4-fl mRNA at any given time. Immunostaining of cultured
FSHD and control cultured muscle cells with four independent
anti-DUX4 monoclonal antibodies showed that approximately
one-out-of-1000 nuclei co-stained with an antibody to the amino-
terminus and an antibody to the carboxy-terminus of DUX4
(Figure 2B), whereas no nuclei in the control cultures showed
double-positive staining.
Both the mRNA analysis and the immunodetection indicate
that approximately 0.1% of FSHD muscle nuclei express DUX4
Figure 1. Expression of DUX4-fl and DUX4-s and D4Z4 in control and FSHD cells. (A) Diagram of D4Z4 repeat array with two most
telomeric full units (large triangles), the last partial repeat, and the adjacent pLAM sequence that contains exon 3. Exons shown as shaded rectangles,
with exon 1 and 2 in the D4Z4 units and exon 3 in the pLAM region. (B) The open rectangle represents the region of D4Z4 and pLAM containing the
DUX4 retrogene, and the solid and dashed lines represent the regions of exons and introns, respectively, in the short splice form (DUX4-s) and the
transcript with the full-length DUX4 ORF (DUX4-fl), which has two isoforms with alternative splicing in the 3-prime untranslated region. First round
PCR for DUX4-fl and DUX4-s was performed with primer sets 1 and 2 and second round PCR with nested primers 3 and 4. Nesting was used to ensure
specificity and because of the very low abundance of DUX4 transcripts, both DUX4-fl and DUX4-s. MAL, represents location of initial amino-acid
codons; *, Stop codons; P, polyadentylation site. (C) Composite image of representative PCR products from FSHD and control muscle biopsies for
DUX4-fl, DUX4-s, and DUX4-fl39. DUX4-fl and DUX4-s are indicated. Variation in size reflects alternative intron usage and the faint intermediate bands
represent background non-DUX4 PCR amplicons frequently associated with repetitive sequence. (D) Representative PCR products of cultured FSHD
and control muscle cells under differentiation conditions. ntc, no template control.
doi:10.1371/journal.pgen.1001181.g001
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expression or stochastic activation of expression that leads to cell
death, or both. Forced expression of DUX4 has been shown to
induce apoptosis in muscle cells [9,11,12]. When DUX4 is
expressed in control human muscle cells by lenti-viral delivery, the
DUX4 protein is distributed relatively homogeneously during the
first 24 hrs and then aggregates in nuclear foci at 48 hrs when the
cells are undergoing apoptosis (Figure 2C, panels c and d). These
DUX4 nuclear foci associated with apoptosis are present in the
nuclei of FSHD muscle cultures (compare panel d in Figure 2C
with panels a–f in Figure 2B). Expression of DUX4-s in control
human muscle cells does not induce apoptosis and does not
accumulate in nuclear foci at 48 hrs (Figure 2, panel e). Therefore,
the data indicates that FSHD muscle cells that express endogenous
full-length DUX4 also exhibit the nuclear foci that are
characteristic of DUX4-induced apoptosis.
DUX4 mRNA and protein are expressed in human testis
Although there is no known function of DUX4 in human
biology, the open reading frame has been conserved [6]. DUX4 is
a retrogene thought to be derived from DUXC [6], or a DUXC-
related gene, but also similar to the DUXA family mouse Duxbl
gene [13]. Therefore, if DUX4 has a biological function it is likely
to be similar to DUXC or Duxbl. Duxbl is expressed in mouse
germ-line cells and we reasoned that because retrotranspositions
entering the primate lineage must have occurred in the germ-line,
then the parental gene to DUX4, either Duxbl or DUXC, must be
expressed in the germ-line. Indeed, we detect the canine DUXC
mRNA in canine testis but not in canine skeletal muscle (data not
shown). Therefore, if DUX4 has a biological function similar to
DUXC or Duxbl, we would anticipate DUX4 expression in the
human germ-line.
We obtained RNA from different adult human tissues and
identified DUX4-fl in testis (Figure 3A), whereas DUX4-s was
present in a subset of differentiated tissues. DUX4-fl was detected
in six additional testis samples, whereas only DUX4-s was detected
in donor-matched skeletal muscle (Figure 3B and 3C). Quantita-
tive PCR (qPCR) showed that human testis samples expressed
almost 100-fold higher amounts of DUX4 mRNA compared to
FSHD muscle biopsies, and almost 15-fold higher amounts
compared to cultured FSHD muscle cells (Figure 3D). Western
analysis using three different DUX4 antibodies identified a protein
of the correct mobility in protein lysates from testes but not in
other cells or tissues that do not express DUX4-fl mRNA,
including control muscle cells (Figure 3E and data not shown).
Furthermore, immunoprecipitation of testis proteins with rabbit
anti-DUX4 antibodies followed by western with a mouse
monoclonal antibody to DUX4 detected the same protein
(Figure 3F). Western analysis of protein extracts from three
additional human testis samples identified a similar band (data not
shown). Immunostaining identified DUX4-expressing cells near
the periphery of the seminiferous tubule that have the large round
nucleus characteristic of spermatogonia or primary spermatocytes
(Figure 4A–4C), and additional more differentiated appearing cells
in the seminiferous tubules were also stained following antigen
retrieval (Figure 4E). The large numbers and nuclear morphology
of the cells staining with DUX4 in the seminiferous tubules,
together with expression of DUX4 in the human germ-cell cell
tumor lines SuSa and 833K [14] (data not shown), leads us to
conclude that DUX4 is expressed in the germ-line lineage. Further
studies will be necessary to determine more precisely the timing
and cell stages of DUX4 expression in the in the testis and to
ascertain whether it has a biological function.
Chromosomes 4 and 10 produce DUX4 mRNA in human
testes
The relatively high abundance of DUX4 mRNA and protein in
human testes suggests a possible role for this protein in normal
development. However, we have previously demonstrated that the
alleles of chromosome 4 and 10 that are non-permissive for FSHD
contain polymorphisms that inhibit polyadenylation of the DUX4
transcript, and, therefore, only the 4A allele would be predicted to
make a DUX4 mRNA [8]. We do not have haplotype information
on the testis donors and it is possible that some might lack the 4A
haplotype entirely. To determine whether only the 4A haplotype
produced stable DUX4 mRNA in human testes, we sequenced
mRNAs from the seven testis samples in a region with informative
polymorphisms regarding transcripts from 4A, 4B, and 10. All testis
mRNA had transcripts from both chromosomes 4 and 10 in
approximately equal amounts (Table 3) based on the informative
polymorphisms(Table 4).Some samples had 4A and 4B haplotypes.
3-prime RACE analysis on testis mRNA demonstrated that the
chromosome 10 transcripts used alternative 3-prime exons with a
polyadenylation signal in exon 7 that is approximately 6.5 kb
further telomeric than the previously identified 4A polyadenyla-
tion site in the pLAM region (GenBank HQ266763) (Figure 5).
Table 1. DUX4 mRNA expression in FSHD and control
biopsies.
Biopsy Code Status Haplotypes
A DUX4-fl DUX4-s 3-prime
F 1998 FSHD A161(10)/n.d. XS O XS
F 0519 FSHD A161(8)/A161 XS O XS
F-0515 FSHD A161(5)/A161 XS O XS
F-0509 FSHD A161(5)/A166H O XS O
F-0531 FSHD A161(7)/A161 O XS O
F-2306 FSHD A161(4)/B163 O X O
F-2331 FSHD A161(3)/B163 X O XS
F-2316 FSHD A161(6)/A168 X O XS
F-2319 FSHD A161(5)/B168 O X O
F-2315 FSHD A161(5)/B168 O O O
C22 contr A161/B163 O X O
C34 contr A161/B163 O XS O
C40 contr A161/B168 O X O
2333 contr A161/A161 O X O
2397 contr A161/B168 O X O
2401 contr A161/B168 O X O
2398 contr A161/B163 O X O
C33 contr A166/B170 O X O
C39 contr A166/B168 O O O
C10 contr B168/B168 O O O
C11 contr B168/B163 O O O
C31 contr B163/B163 O O O
2318* contr B169/B166 O O O
C20 contr B168/B168 O O O
C38 contr B162/B163 O O O
AChrosome 4 haplotype. For FSHD the number in paratheses indicates the
number of D4Z4 units on the contracted allele; n.d., indicates that the
haplotype of the second allele was not determined.
X, product present; XS, product sequenced; O, product absent.
*has contracted 10qA allele with 9 repeats.
doi:10.1371/journal.pgen.1001181.t001
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(Genbank HQ266764 and HQ266765), but the exon 3 polyad-
enylation site associated with the permissive allele is preferred
(data not shown). The 4B transcripts do not use either the exon 3
or exon 7 polyadenylation sites since the 4B haplotype lacks these
regions, however, we have not yet identified the full 3-prime
sequence of the DUX4 mRNA from the 4B chromosome. Re-
analysis of the muscle cell line, muscle biopsy, and somatic tissue
transcripts did not identify any DUX4 mRNA utilizing the exon 7
polyadenylation site from either chromosome 10 or 4, including a
control sample with a contraction to 9 copies of D4Z4 on
chromosome 10 (biopsy 2318 in Table 1, data not shown). We
conclude that chromosome 10 DUX4 transcripts in the testes use a
distal exon 7 polyadenylation signal, whereas this region is not
used in somatic tissues, even when the chromosome 10 D4Z4
array has contracted to ten repeats. Therefore, polyadenylated
DUX4 mRNA from chromosomes 4 and 10 are present in the
testis, but only chromosome 4A produces polyadenylated
transcripts in somatic tissues.
Developmental regulation of alternative splicing
suppresses DUX4-fl from chromosome 4
The expression of DUX4-fl mRNA in unaffected human testes
and the expression of DUX4-s in some unaffected somatic tissues,
including skeletal muscle, suggested a developmental regulation of
splice site usage in the DUX4 transcript. To directly determine
whether the transition between DUX4-fl and DUX4-s expression
is developmentally regulated, we generated induced pluripotent
stem (iPS) cells from FSHD and control fibroblasts by expression
of SOX2, OCT4, and KLF4 transcription factors from Moloney
murine leukemia virus vectors [15]. Stem-cell clones had normal
karyotypes, exhibited the expected cellular and colony morphol-
ogy, contained tissue non-specific alkaline phosphatase activity,
and expressed embryonic antigens (Figure 6A). RT-PCR demon-
strated expression of stem cell markers NANOG, HTERT, cMYC,
and endogenous transcripts from OCT4, SOX2, and KLF4
(Figure 6B). Pluripotency was demonstrated by the ability to form
teratomas containing tissues derived from ectoderm, endoderm,
and mesoderm (See Figure 6A). We used these characterized iPS
Table 2. DUX4 mRNA expression in FSHD and control cell lines.
Cell Code Status Haplotypes Cell type
A DUX4-fl DUX4-s 3-prime
MB73 FSHD A161(8)
B/161
C MB X X X
MB183 FSHD A161(5)/B163 MB X O X
MB148 FSHD A161(3)/A161 MB X O X
MB200 FSHD2 A161(14)/B168 MB X XS X
MB216 FSHD A161(6)/A168 MB O O O
MB219 FSHD A161(5)/B168 MB O O O
MB230 contr A161/163
A MB O X O
MB196 contr A161/163
A MB O X O
MB226 contr A161/A161 MB O X O
MB135 contr A161/B163 MB O XS O
MB73 FSHD A161/161 MT X X XS
MB183 FSHD A161/B163 MT X O X
MB148 FSHD A161/A161 MT X O XS
MB200 FSHD2 A161/B168 MT XS O XS
MB216 FSHD A161/A168 MT X O XS
MB219 FSHD A161/B168 MT X O X
MB230 contr A161/163
A MT O X O
MB196 contr A161/163
A MT O X O
MB226 contr A161/A161 MT O X O
MB135 contr A161/B163 MT O X O
M83-9 contr A161/168
A fibro O XS O
M83-9 contr iPS XS OX
M83-9 contr EB O X O
43-1 FSHD A161(5)/A161 fibro XS OO
43-1 FSHD iPS XS OX
43-1 FSHD EB X O XS
83-6 FSHD A161(7)/B168 fibro XS XS X
83-6 FSHD iPS X O X
83-6 FSHD EB X O XS
AMB, myoblasts; MT, myotubes; fibro, fibroblasts; iPS, induced pleuripotent stem cells, EB, embryoid bodies.
BNumber of repeats on contracted allele, if known.
CAssignment of the second 4q allele variant is incomplete.
n.d., not tested; X, product present; XS, product sequenced; O, product absent.
doi:10.1371/journal.pgen.1001181.t002
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parental fibroblasts, undifferentiated iPS cells, and in the iPS cells
after differentiation into embryoid bodies.
DUX4-s, but not DUX4-fl, was detected in control fibroblasts.
In contrast, iPS cells derived from the control fibroblasts expressed
DUX4-fl, whereas differentiation of these cells to embryoid bodies
resulted in a switch to the expression of DUX4-s and loss of
DUX4-fl transcripts (Table 2 and Figure 6C). In contrast, DUX4-
fl was detected in FSHD fibroblasts and the iPS cells and embryoid
bodies derived from FSHD fibroblasts. As expected, DUX4-fl39
was detected in samples expressing DUX4-fl. (The relative
amounts of DUX4-fl in a subset of iPS cells is shown in
Figure 3D and a band migrating at the size of DUX4 was
detected on a western with an anti-DUX4 antibody (data not
shown)). DUX4-fl was detected in some human ES cell lines, but
at much lower levels compared to the iPS cells (data not shown).
All of the splice donor and acceptor sites in the multiple
alternative splicing events in the 3-prime UTR have consensus
splice donor and acceptor sequences. In contrast, the splice donor
in the ORF that produces DUX4-s is a non-canonical donor
sequence and would normally not be favored for splicing. Recent
studies have indicated that repressive chromatin modifications can
favor splice donor usage [16] and we tested whether the degree of
H3K9me3 correlated with the usage of the DUX4-s splice site.
Chromatin immunoprecipitation showed that the control fibro-
blasts and embryoid bodies with DUX4-s expression had relatively
higher levels of trimethylation of lysine 9 in histone H3
(H3K9me3), a repressive chromatin modification, compared to
the control iPS cells, which express DUX4-fl (Figure 6D). The
FSHD cells maintained relatively low levels of H3K9me3 in both
iPS and differentiated cells. These findings are consistent with
previous studies showing decreased H3K9me3 at the D4Z4 region
in FSHD1 and FSHD2 [3] and suggest a correlation between the
relatively higher levels of repressive chromatin modifications and
the use of the cryptic splice donor to produce DUX4-s.
Discussion
We note that prior studies reported the presence of polyade-
nylated DUX4 transcripts in a small number of samples of
cultured FSHD muscle cells but not in control muscle cells [7,8].
Our study both confirms and significantly extends these prior
studies by (a) including a larger number of FSHD muscle cell
cultures, (b) assaying controls that have a permissive 4A
chromosome and non-permissive 4B chromosomes, (c) extending
the analysis to mRNA from primary muscle biopsies of FSHD and
haplotype-matched controls, (d) identifying the DUX4-s splice
form of the DUX4 mRNA in control cells and showing that the
qualitative difference between control and affected muscle is
splice-site usage and not production of DUX4 mRNA; (e)
demonstrating that the very low abundance of DUX4 mRNA in
FSHD muscle represents a small percentage of nuclei with
relatively high abundance mRNA and protein; (f) demonstrating
that relatively high amounts of the DUX4 mRNA are expressed in
the human testes and pluripotent cells and that developmental
regulation is achieved by a combination of chromatin-associated
splice-site usage and polyadenylation site usage.
Together our data provide the basis for a specific model of
FSHD pathophysiology: (1) full-length DUX4 is produced from
the last D4Z4 unit in early stem cells; (2) in differentiated tissues,
Figure 2. A small number of FSHD muscle cells express a relatively large amount of DUX4. (A) RT-PCR for full length DUX4 (DUX4-fl39)
was performed in duplicate on polyadenylated RNA isolated from ten pools of 600 cultured FSHD muscle cells (lanes 1–10) and a single pool of
10,000 cells (lane 11). The presence of DUX4 mRNA in one-half of the pools indicates that approximately one cell per 1000 is expressing DUX4 mRNA.
NTC, no template control. (B) Cultured FSHD muscle cells were differentiated and immunostained with monoclonal antibodies to DUX4. Cells were
co-stained with the E5-5 rabbit monoclonal antibody to the DUX4 C-terminal region (panels a, c, e) and the P2G4 mouse monoclonal antibody to the
N-terminal region (panels b,d,f), or co-stained with the P4H2 mouse monoclonal antibody to the C-terminal region and the E14-3 rabbit monoclonal
antibody to the N-terminal region. Approximately 1 cell per 1000 showed nuclear staining and the co-localization of both the n-terminal and c-
terminal regions indicates that these cells are expressing the full-length DUX4 protein. No positive nuclei were apparent in the control muscle
cultures. (C) Control human muscle cultures infected with a lenti-virus expressing full length DUX4 (a–d) or DUX4-s (e) co-stained with P4H2 (panels a,
c) and E14-3 (panels b, d, e). In the cells expressing DUX4-fl, at 24 hrs there is a relatively homogenous nuclear distribution of DUX4 (a,b), whereas at
48 hrs as the cells are undergoing apoptosis DUX4 staining becomes more focal and punctate (c,d), similar to the punctate DUX4 staining in the
FSHD muscle cells in panel B. Expression of DUX4-s does not induce apoptosis (data not shown) and the DUX4-s protein maintains a relatively
homogenous nuclear distribution at 48 hrs (e).
doi:10.1371/journal.pgen.1001181.g002
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and DUX4 expression is repressed; (3) in the residual transcripts
that escape repression, an alternative first-intron splice donor is
utilized to produce DUX4-s instead of DUX4-fl; (4) contraction of
the D4Z4 arrays impedes the conversion to repressive chromatin
and the transition from DUX4-fl to DUX4-s, resulting in
expression of the full-length DUX4 in skeletal muscle and possibly
other tissues; and (5) the very low levels of full-length DUX4
Figure 3. Expression of DUX4-fl in human tissues. (A) RT-PCR of RNA from human tissues showing DUX4-fl in the testis sample (Testis-1) and
DUX4-s in ovary heart and liver. Note that each sample is from an unknown individual and their genotype is not known. (B) RT-PCR of three additional
testis samples and matched skeletal muscle RNA from the Testis-1 and Testis-4 donors. (C) RT-PCR of the full-length DUX4 ORF (nested with 36 total
cycles) in muscle (M) and testes (T) RNA from the same individuals, showing expression in testes and not in muscle. Numbers indicate Testis-1, 4, 7, 6,
5. (D) Quantitative RT-PCR of DUX4-fl39 showing relative abundance in muscle cells, muscle biopsies, human testis and othr indicated cells. The
sample with the highest expression was set at 100% and the number of copies per cell roughly estimated based on titration of input DNA. H9-ES,
human embryonic cell line H9; M83-9 iPS, iPS line made from control fibroblasts; 43-1 series are the fibroblast, iPS, and EB cells from an FSHD
fibroblast line; MB183 and MB148, FSHD muscle cultures under growth (MB) and differentiation (MT) conditions; F-2331 and F-2316, FSHD muscle
biopsy samples; hTestis, human testis. (E) Western detection of DUX4 protein in whole cell extracts from tissues and cell lines using a rabbit
monoclonal antibody (E14-3) raised to the aminoterminus of the human DUX4 protein. Lanes: 1-control muscle culture; 2-HCT116 cell line; 3-mouse
testis; 4-human testis; 5-C2C12 cells transfected with human DUX4 expression vector; 6-C2C12 cells. Specificity of the antibody is indicated by
selective detection of DUX4 protein in C2C12 cells transfected with a DUX4 expression vector, pCS2-DUX4 (note that this vector contains two ATG
codons resulting in the standard DUX4 protein and an in-frame slightly larger protein accounting for the two bands on the western), compared to
untransfected C2C12. Human testis has a single reactive band that migrates marginally slower than the transfected standard DUX4 species in C2C12
cells. This DUX4-reactive band is not present in mouse testis extract (note that mice do not have a highly conserved DUX4), HCT116 human colon
cancer cells, nor unaffected myotubes (MB196-36hr). Similar results were obtained with an additional DUX4 antibody (E5-5) raised to the
carboxyterminal region of DUX4 (data not shown)) and on protein extracts from two additional testis samples (data not shown). (F)
Immunoprecipitation of indicated protein extracts with the E14-3 rabbit monoclonal to the N-terminal region of DUX4 followed by western with the
P4H2 mouse monoclonal to the C-terminal region of DUX4 demonstrating that the protein recognized by the rabbit anti-DUX4 is also recognized by
an independent mouse monoclonal to DUX4. Lanes: 1-HCT116 cell line lysate; 2- Testis protein lysate; 3-C2C12 cells transfected with DUX4 expression
vector.
doi:10.1371/journal.pgen.1001181.g003
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expression in a small sub-population of cells. Several groups have
shown that expression of full-length DUX4 in muscle cells can
induce pathologic features of apoptosis and expression of PITX1
[7,11,17,18]. In contrast, expression of DUX4c, a DUX4-like
protein that lacks the carboxyterminal portion of DUX4, does not
induce apoptosis [18]. Therefore, it is reasonable to believe that
expression of DUX4-fl might induce muscle cell damage in
FSHD, whereas DUX4-s expression would not be harmful to the
cells. Indeed, FSHD muscle cells expressing the endogenous
DUX4 have nuclear foci of DUX4 characteristic of the foci that
appear during early stages of apoptosis when DUX4 is
exogenously expressed in human skeletal muscle cells (see
Figure 2), suggesting, but not yet proving, that these DUX4
expressing cells might be initiating a process of nuclear death.
The observed association of decreased H3K9me3 of D4Z4 with
detectable levels of DUX4-fl mRNA suggests a specific mechanism
of regulating DUX4 splicing. Previously [9], we demonstrated
bidirectional transcription of the D4Z4 repeats with the generation
of small si/mi/pi-like RNA fragments and suggested that the small
RNAs generated from D4Z4 might function to suppress DUX4
expression in a developmental context, a suppression mechanism
observed for other retrogenes [19,20,21]. A recent publication
demonstrated that the small RNAs mediating heterochromatin
formation also regulate splice-donor usage, either by targeting the
nascent transcripts or by altering the rate of polymerase
progression through condensed chromatin [16,22]. Therefore,
the repressive chromatin associated with D4Z4 in differentiated
cells might facilitate the usage of the non-canonical splice donor to
generate DUX4s, either through siRNAs from the region or
through the impediment of polymerase progression, whereas the
more permissive chromatin in FSHD and pluripotent cells might
favor polymerase progression through to the consensus splice
donor and generate DUX4-fl.
A recent study by Lemmers et al [8] identifies sequence variants
on 4A necessary to produce polyadenylated DUX4 mRNA
transcripts in somatic tissues. Our results are consistent with these
findings since we have not been able to identify polyadenylated
transcripts from non-permissive alleles in somatic tissues. In
contrast, we do find alternative distal polyadenylation usage for
DUX4 mRNA from non-permissive alleles in the testis. Develop-
mentally regulated polyadenylation site usage has been described
for other genes [23] and appears to be one additional mechanism
of silencing expression of the DUX4 retrogene in somatic cells.
Our finding that the wild-type chromosomes 4 and 10 express a
full-length DUX4 mRNA in human testes, most likely in the germ-
line, and that the protein is relatively abundant suggests that
DUX4 might have a normal role in development. This is
supported by the expression of canine DUXC in germ-line tissue
(L. Geng, unpublished data). In addition, a DUX4-like gene in the
mouse, Duxbl, is expressed in mouse germ-line cells in both
spermatogenesis and oogenesis, as well as in early phases of skeletal
muscle development [13]. Similar to DUX4, Duxbl has develop-
mentally regulated splicing to produce a full-length protein and a
protein truncated after the double homoeodomains and studying
the roles of Duxbl in germ-line and muscle development in mouse
Figure 4. Expression of DUX4 in the testis. Frozen sections of human testis stained with anti-DUX4 monoclonal antibodies P2B1 and E5-5
together (A), or P2B1 (B), or E5-5 (C) individually, compared to an isotype control (D). Arrowheads indicate a few of the many nuclei that show a
brown antibody-dependent precipitate superimposed on the blue hematoxylin stained nuclei. (E) Antigen retrieval reveals a larger number of more
differentiated germ-line cells stained with the P2B1 antibody, compared to an isotype control (F). Because of the range of nuclear morphologies and
relatively large numbers of positive cells, the DUX4 expressing cells in the germ line lineage at a range of differentiation stages.
doi:10.1371/journal.pgen.1001181.g004
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that our study describes the expression of human DUX4 in testes
but we believe it is likely to be expressed in oogenesis as well.
Limited access to appropriate tissue has limited our ability to
carefully examine expression in cells of the ovary.
Generating new genes through retrotransposition is a common
mechanism of mammalian evolution [24], particularly for genes
with a role in germ cell development. Recently an FGF4 retrogene
was identified as causing the short-legged phenotype in many dog
breeds [25], indicating that retrogenes can direct dramatic
phenotypic evolution in a population. Our study demonstrates
that the expression of the DUX4 retrogene is developmentally
regulated and might have a role in germ-line development, and, if
similar to Duxbl, possibly in aspects of early embryonic muscle
development. Maintaining the DUX4 retrogene in the primate
lineage suggests some selective advantage compared to maintain-
ing the parental gene itself. Based on current knowledge, this could
be due to a function in germ-line development, or to a modulation
of muscle mass in primate face and upper extremity. In this regard,
it is interesting to speculate that a normal function of the DUX4
retrogene might be to a regulate the development of facial and
upper-extremity muscle mass in the primates, and that FSHD
represents a hypermorphic phenotype secondary to inefficient
developmental suppression. Alternatively, the persistent expression
of full-length DUX4 might induce a neomorphic phenotype
unrelated to an evolutionarily selected role of DUX4. In either
case, our findings substantiate a comprehensive developmental
model of FSHD and demonstrate that FSHD represents the first
human disease to be associated with the incomplete developmental
silencing of a retrogene array that is expressed in pluripotent stem
cells and in normal development.
Materials and Methods
Ethics statement
This study used pre-existing and de-identified human tissue
samples from tissue repositories and commercial sources and was
approved by the Fred Hutchinson Cancer Research Center and
the University of Washingtion Institutional Review Boards.
Animal studies were approved by the University of Washington
Institutional Animal Care and Use Committee and followed the
Assessment and Accreditation of Laboratory Animal Care
guidelines.
Muscle biopsies, cultures, and human RNA and protein
Muscle biopsy samples were collected from the vastus lateralis
muscle of clinically affected and control individuals using
standardized needle muscle biopsy protocol and cell cultures were
derived from biopsies as described on the Fields Center website:
http://www.urmc.rochester.edu/fields-center/protocols/documents/
PreparingPrimaryMyoblastCultures.pdf. The sex, age, and sever-
ity score for the FSHD muscle biopsies were: F1998 (M, 43, 2);
F0519 (M, 43, 4); F0515 (F, 48, 2); F0509 (M, 47, 2); F0531 (F, 47,
2); F2306 (F, 46, ND); F2331 (F, 56, 4); F2316 (F, 34, 5); F2319
(M, 52, ND); F2315 (F, 40, 3). Pathologic grading scale is 0–12
(from normal to severe) based on a score of 0–3 for each of four
parameters: muscle fiber size/shape; degree of central nucleation;
presence of necrotic/regenerating fibers or inflammation; and
degree of fibrosis. Controls were selected in the same age range
and sex representation. Muscle cell culture MB216 and muscle
biopsy F2316 are from the same individual, otherwise the muscle
cultures were derived from other individuals. RNA and protein
lysates from human tissues were purchased from BioChain
(Hayward, CA) and Origene (Rockville, MD).
RT-PCR for DUX4-fl, DUX4-s, and DUX4-fl39
Total RNA was isolated from muscle biopsies and cultured cells
using Trizol (Invitrogen) and then treated with DNase I for
15 minutes using conditions recommended by Invitrogen with the
addition of RNaseOUT (Invitrogen) to the reaction. DNase
reaction components were removed using the RNeasy (Qiagen)
system and RNA eluted by two sequential applications of 30 mlo f
RNase-free water. Volume was reduced by speed vac and 1.5–
2 mg of RNA used for first strand cDNA synthesis. RNA from
adult human tissues was purchased from Biochain and had been
DNase-treated by the supplier. First strand synthesis was
performed using Invitrogen SuperScript III reverse transcriptase
and Oligo dT primers according to manufacturer’s instructions at
55u for 1 hour followed by digestion with RNase H for 20 minutes
at 37u. Finally, the reactions were cleaned using the Qiaquick
(Qiagen) pcr purification system and eluted with 50 ml of water.
Primary pcr reactions were performed with 10% Invitrogen PCRx
enhancer solution and Platinum Taq polymerase using 10–20% of
the first strand reaction as template in a total reaction volume of
20 ml in thin wall MicroAmp (Applied Biosystems) reaction tubes.
Nested pcr reactions used 1 ml of the primary reaction as template.
Primers for Dux4-fl and -s detection in biopsy and cultured cell
samples were 14A forward and 174 reverse, nested with15A (or
16A) forward and 175 reverse. Primers for 39 detection were 182
forward and 183 reverse nested with1A forward and 184 reverse.
All primer sequences are listed in Table 5.
Dux4-fl and -s in adult human tissues were detected using 14A
forward and 183 reverse, then nested with 15A forward and 184
reverse primers. Pcr cycling conditions were as follows for both
primary and nested pcr: 94u 5 minutes denaturation, 35 cycles of
94u for 300,6 2 u for 300 and 68u for 2.5 minutes or 1 minute
Table 3. Haplotype identification of DUX4 mRNA in human
testis.
Sample Code %10A
A %4 A %4 B Total Number
B
T1 22 78 0 9
T2 60 40 0 10
T3: 8606 22 67 11 9
T4: H12817 56 0 44 9
T7: N30 56 22 22 9
T6: N21 20 80 0 10
T5: N11 22 78 0 9
Total 38 53 9 64
APercentage of the sequences containing SNPs of each haplotype, see Table 4
for sequence polymorphisms.
BNumber of sequenced cDNA.
doi:10.1371/journal.pgen.1001181.t003
Table 4. Diagnostic polymorphisms in exon 2.
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of 7 minutes at 68u was included. Pcr products were examined on
2% NuSieve GTG (Lonza) agarose gels in TBE.
Pooled PCR for DUX4
To assess for stochastic expression of DUX4 in affected muscle
cells, FSHD primary myoblasts were trypsinized and collected at
confluence or after differentiation for 96 hr. Cells were counted
and split into pools of 100-cell, 600-cell, or 10,000-cell aliquots.
RNA was extracted from individual aliquots using Dynabeads
mRNA DIRECT Kit (Invitrogen) following manufacturer’s
instructions. Bound polyadenylated mRNA was used directly for
reverse transcription reaction with SuperScript III using on-bead
oligo dT as primer. Synthesis was carried out at 52uC for 1 hr,
terminated at 70uC for 15 min, followed by 15 min of RNase H
treatment. 2 uL of cDNA product was used for nested DUX4-fl39
PCR as described above.
RT-PCR for transcripts from chromosomes 10 and 4
Pcr reactions were performed on RT reactions generated as
described above and using nested primer sets to sequences in
exons 1 and 2 that are common to alleles on chromosomes 4 as
well as 10. Transcripts were detected using primers 1A and 187
followed by nesting with 138S and 188 (Table 5). Diagnostic
polymorphisms (underlined) in the 59 end of exon 2 were used to
assign allele origins of transcripts:
Quantitative RT-PCR for DUX4-fl39
For quantitative PCR, 1 ug of DNase’d RNA was used for first
strand cDNA synthesis. Reverse transcription was performed as
above, except at 52uC for the synthesis reaction followed by
15 minutes of RNase H treatment and the Qiaquick purification
eluted in 30 ml of water. One round of PCR reactions were
performed using the same reagents as above and 2 uL of purified
cDNA template. Primers for full length detection were 92
forward and 116 reverse (Table 5). PCR cycling conditions were
as follows: 95uC 5 min denaturation, 36 cycles of 95uC for 300,
62uCf o r3 0 0 and 68uC for 1 min, and final extension of 5 min at
68uC. Sequence of the product matched DUX4. A standard
curve for DUX4 template copies was generated from PCR
reactions using the same primers and cycling conditions but with
known dilutions of a plasmid containing full length DUX4
cDNA in water. Test sample PCR reactions and standard PCR
reactions were run in triplicate and examined on the same 1%
agarose/TBE gels stained with SYBR Gold (Invitrogen) for
40 min per manufacturer instructions. Fluorescence was detect-
ed with Typhoon Trio Multi-mode Imager (GE Healthcare):
excitation laser 488 nm; emission filter 520DP 40, PMT 500 V,
100 mm resolution. Histogram analysis was performed to ensure
no signals were saturated. Gel band intensities were quantified
with ImageQuant TL v2005 (GE Healthcare) software. Esti-
mates for the copies of DUX4 full length template in the test
samples were interpolated from the line of best fit of the
dilutional standards, with the lowest visible dilutional signal
setting the detection limit. The interpolated number was doubled
to adjust for the single-stranded cDNA input in contrast to the
double-stranded plasmid standard input. This resulted in an
estimated copy number of DUX4 full-length per ug of total
RNA. Final copy number estimates per cell were calculated
based on assumptions of 100% efficient reverse transcription and
3.3 pg of total RNA per cell.
Figure 5. Alternative exon and polyadenylation site usage in germ-line and somatic tissues. (A) Schematic of last D4Z4 unit, last partial
repeat, and distal exons. Exon 7 is approximately 6.5 kb from the polyadenylation site in exon 3. DUX4-fl from FSHD muscle contains exons 1-2-3.
DUX4-s uses a non-consensus splice donor in the middle of exon 1 to create a short exon 1: 1s-2-3. Both are derived exclusively from chromosome 4A
in muscle and other sampled somatic tissues. Germ line tissue expresses the 4A transcript with exons 1-2-3 but also expresses both 4A and 10A
transcripts with exons 1-2-6-7. We have also identified a transcript in testis that shows a 1-2-4-5-6-7 splice usage. (B–E) Exon sequences (upper case
letters) with flanking genomic sequence (lower case letters). B, Exon 4. C, Exon 5. D. Exon 6. E. Exon 7. Exon 6 and 7 sequences are from a cDNA
assigned to chromosome 10, exon 4 and 5 sequences are from a cDNA assigned to 4A161.
doi:10.1371/journal.pgen.1001181.g005
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Pluripotent Stem (iPS) cells from unaffected and FSHD-affected individuals. Human iPS cell lines were generated from skin fibroblasts cultured from
an unaffected (M83-9) and two FSHD-affected individuals (FSHD83-6 and FSHD43-1). Human ES cells (HESC) are also shown. Each iPS cell line was
generated by transduction of fibroblasts with murine retrovirus vectors encoding Human SOX2, OCT4, and KLF4. Colonies developed approximately
20 days after infection and had the characteristic growth morphology of an iPS cell with flat, well organized colonies, sharply defined colony and cell
borders, high nuclear to cytoplasmic ratio, and prominent single nucleoli. Cells contained tissue non-specific alkaline phosphatase activity (AP), had
normal karyotypes, and were immunoreactive (green) for Stage Specific Embryonic Antigen 4 (SSEA4), NANOG, OCT4, and TRA-1-60. 4,6-Diamidino-2-
phenylindole (DAPI) staining (blue) indicates total cell content per image. Bottom panel shows hematoxylin and eosin stained tissue sections of
teratomas. Teratomas that developed in SCID-Beige mice after intramuscular injection of iPS cells generated from skin fibroblasts of a normal
individual (M83-9) or two different FSHD-affected individuals (FHSD83-6 and FSHD43-1). Endoderm-derived tissue is identified by a gut-like structure
surrounded by smooth muscle, parenchymal tissue, and lined with a columnar endothelium. Mesoderm-derived tissue is identified by bone (M83-9)
or by the presence of cartilage containing chondrocytes (FSHD83-6 and FSHD43-1), and ectoderm-derived tissue is identified by the presence of
pigmented neural epithelium (M83-9 and FSHD43-1) or neural rosettes (FSHD83-6). (B) Total cellular RNA was purified from human dermal fibroblasts
(HDF), iPS cells used in this study (M83-9, FSHD83-6, FSHD43-1), and Human ES cells (HESC). The presence of RNA transcripts from the genes indicated
was detected by priming reverse transcription reactions with oligo dT and PCR amplification of cDNA with oligonucleotides complementary to the
sequence of the genes listed (28 cycles). Priming oligonucleotides used for OCT4, SOX2, and KLF4 amplification were specific for non-vector encoded
transcripts. As a positive control, RNA from Human embryonic stem cells (HESC) was processed in parallel. Water instead of RNA was used as a
negative control, and reverse transcriptase was left out of the cDNA synthesis step (-RT) to demonstrate RNA purity, and RNA transcripts from
glyceraldehyde phosphate dehydrogenase (GAPDH) were amplified to demonstrate RNA integrity. (C) RT-PCR of DUX4 mRNA in iPS cells derived from
control or FSHD fibroblasts. M8 (M83-9), control fibroblast line; F4 (FSHD 43-1) and F8 (FSHD 83-6), FSHD fibroblast line. (D) Chromatin
immunoprecipitation (ChIP) analysis of H3K9me3 at the 59-region of DUX4 in control and FSHD fibroblasts, induced pluripotent stem (iPS) cells, and
embryoid bodies (EB) differentiated from the iPS. Bars represent relative enrichment by real-time PCR with primers previously described and
confirmed as specific to D4Z4. The H3K9me3 IP signals were normalized to control IgG IP and to input, presented as mean 6 stdev.
doi:10.1371/journal.pgen.1001181.g006
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To assess for the full coding region of DUX4, three rounds of
PCR were performed on cDNA, totaling 36 cycles. Conditions for
each round were as follows: 95uC for 59, 3 cycles of 95uC for 300
and 68uC for 19330, 3 cycles of 95uC for 300 and 65uC for 300 and
68uC for 19330, 6 cycles of 95uC for 300 and 62uC for 300 and
68uC for 19330. 3 uL of primary PCR was used in the secondary
PCR, and 3 uL of secondary PCR were used in the tertiary PCR.
Primers for successive rounds of pcr (133, 134, 135, 136, 137, and
138G) are listed in Table 5.
39 RACE for DUX4 in human testes
39 RACE was performed on total RNA using Invitrogen Gene
Racer kit essentially as described. Prior to pcr with gene specific
primers and the GeneRacer 39 primers the RT reaction was
cleaned using Qiaquick (Qiagen) spin columns as described above.
Gene specific forward primers were 182 and 1A (nesting). Pcr
products were gel purified, cloned into TOPO 4.0 (Invitrogen) and
sequenced.
Generation of induced pluripotent stem (iPS) cells
iPS cells were generated by forced expression of human OCT4,
SOX2, and KLF4 using the retroviral vectors essentially as
previously described (1). MLV vectors (pMXs-hOCT4, pMXs-
hSOX2, and pMXs-hKLF4) were purchased from Addgene
(www.addgene.com, Cambridge, MA) and vector preparations
were generated by transient transfection of Phoenix-GP cells (2)
with pCI-VSV-G and vector plasmids (1:1 ratio), replacing the
culture medium 16 and 48 hours later, harvesting and filtering
(0.45 um pore size) conditioned medium after a 16 hour exposure
to cells, and concentrating 50 to 100-fold by centrifugation (3).
Transduction with MLV vectors was performed with polybrene
(4ug/ml concentration) (Sigma-Aldrich Corp., St. Louis, MO)
added to the medium. iPS cell colonies were identified by their
characteristic morphology, cloned by microdissection, and ex-
panded on irradiated mouse embryo fibroblasts (6000 rads) for
further characterization. Typically, 5610
4 fibroblasts cultured in
DMEM plus 10% FBS were seeded to a 9.4 cm
2 well on day
minus 1, the medium was replaced with medium containing
vectors and polybrene on day 0, and changed again to medium
with DMEM plus 10% FBS on day 1. Cells were detached with
trypsin and seeded to five 55 cm
2 dishes on day 2 and medium
changed on day 4. On day 6 cells are again detached with trypsin
and 5610
5 cells seeded to 55 cm
2 dishes containing 7610
5
irradiated mouse embryo fibroblasts (6000 rads) in human ES cell
culture medium (see below). Medium is replaced every other day
and colonies with typical morphology of iPS cells appear between
day 20 and day 30 post infection. Colonies are mechanically
dissected using drawn Pasteur pipettes and seeded to mouse
embryo fibroblast feeder layers for culture and passaged every 2–3
days using 2 u/ml dispase.
Stem cell culture
iPS cells and Human ES cells were grown in a solution of
DMEM:F12 (1:1) with 3.151 g/L glucose, supplemented with L-
Glutamine (Invitrogen), non-essential amino acids (10 mM (1006)
liquid, Invitrogen, # 11140-076), sodium pyruvate (100 mM
(1006), liquid, # 11360-070), 20% knockout serum replacer (#
10828010) (Invitrogen, Carlsbad, CA), 1mM beta-mercapto-
ethanol (Sigma, St. Louis MO), and 5 ng/ml basic fibroblast
growth factor (Peprotech, #AF-100-18B ). Cells were generally
cultured in 0.1% gelatin coated dishes containing irradiated mouse
embryo fibroblasts at a density of 1.3610
4 cells/cm
2. When cells
were used as a source of RNA, DNA, or protein, they were
cultured on matrigel (1:60 dilution, BD biosciences, #356234)
coated dishes in medium conditioned by exposure to confluent
layers of mouse embryo fibroblasts over a 3 day period. Cells were
passaged a minimum of 4 times under these conditions before
DNA, RNA, or protein was harvested.
Detection of embryonic antigens in iPS cells
iPS cells were evaluated for the presence of tissue non-specific
alkaline phosphatase activity by fixing colonies in phosphate
buffered saline solution containing 0.5% gluteraldehyde, and
washing 63 in PBS. A staining buffer containing 100 mM Tris
pH 8.5, 100 mM NaCL, 50 mM MgCl2, 0.1 mg/ml 5-Bromo-4-
chloro-3-indolyl phosphate (xphos) and 1 mg/ml p-Nitro-Blue
tetrazolium chloride (NBT) (Sigma-Aldrich, St. Louis, MO, USA)
was used to detect tissue non-specific alkaline phosphatase activity.
Stage Specific embryonic antigen 4 (SSEA4) was detected using
mouse monoclonal MC-813-70 and goat anti-mouse FITC
conjugated secondary. TRA-1-60 was detected using mouse
monoclonal TRA-1-60 (Millipore, Billerica, MA), and goat anti-
mouse FITC conjugated secondary (Millipore, Billerica, MA).
Table 5. Primer sequences.
1A 59 GAGCTCCTGGCGAGCCCGGAGTTTCTG 39 forward
14A 59 CCCCGAGCCAAAGCGAGGCCCTGCGAGCCT 39 forward
15A 59 CGGCCCTGGCCCGGGAGACGCGGCCCGC 39 forward
16A 59 GGATTCAGATCTGGTTTCAGAATCGAAGG 39 forward
92 59 CAAGGGGTGCTTGCGCCACCCACGT 39 forward
116 59 GGGGTGCGCACTGCGCGCAGGT 39 reverse
133 59 ATGGCCCTCCCGACACCCTCGGACAGCACC 39 forward
134 59 CTCGGACAGCACCCTCCCCGCGGAAGCCCG 39 forward
135 59 GGAAGCCCGGGGACGAGGACGGCGACGGAG 39 forward
136 59 CTAAAGCTCCTCCAGCAGAGCCCGGTATTCTTCCTC 39 reverse
137 59 CCCGGTATTCTTCCTCGCTGAGGGGTGCTTCCAG 39 reverse
138G 59 GGGGTGCTTCCAGCGAGGCGGCCTCTTCCG 39 reverse
138S 59 CGGAGTTTCTGCAGCAGGCGCAACCTCTCCT 39 forward
174 59 GTAACTCTAATCCAGGTTTGCCTAGA 39 reverse
175 59 TCTAATCCAGGTTTGCCTAGACAGC 39 reverse
182 59 CACTCCCCTGCGGCCTGCTGCTGGATGA 39 forward
183 59 CCAGGAGATGTAACTCTAATCCAGGTTTGC 39 reverse
184 59 GTAACTCTAATCCAGGTTTGCCTAGACAGC 39 reverse
187 59 CTGCTGGTACCTGGGCCGGCTCTGGGATCCC 39 reverse
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(Northern Lights) conjugated antibody (NL493, R & D systems,
Minneapolis, MN). Human OCT4 was detected with a rabbit
polyclonal (Abcam, Cambridge, MA) and goat anti rabbit
secondary conjugated with the Alexa 488 flurophore (Invitrogen,
Carlsbad, CA). Cell karyotypes were determined by the University
of Washington Cytogenetics laboratory.
Teratoma formation and staining
Induced pluripotent stem cells were detached from culture
dishes with dispase (2 units/ml working concentration), 2610
6
cells resuspended in F12:DMEM (1:1 mixture) medium without
supplements, and injected into the femoral muscle of SCID-Beige
mice (CB17.B6-Prkdc
scidLyst
bg/Crl Charles River, Stock # 250).
Mice were maintained under biosafety containment level 2
conditions and palpable tumor masses developed approximately
6 weeks later. When a tumor mass was palpable the mice were
sacrificed and tumor tissue fixed for several days in phosphate
buffered saline solution containing 4% formaldehyde, and
imbedded in paraffin. Sections of the tumor (5 micron thickness)
were placed on slides and stained with hematoxylin and eosin
using standard protocols.
Embryoid body formation
Human iPS were prepared for embryoid body formation by
expanding cell numbers on mouse irradiated feeder layers,
detaching colonies with dispase, triturating with a Pasteur pipette,
and seeding colony fragments to dense layers of mouse embryo
fibroblast feeders (5610
4 irradiated mef/cm
2) prior to EB
formation. Four days later densely grown colonies from a
55 cm
2 dish were treated with dispase and gently detached by
pipetting or scraping. Colony fragments were washed several times
and seeded (1:1) to Ultra Low Attachment 55 cm
2 culture dishes
(Corning, Corning, NY) in DMEM supplemented with 20% Fetal
Bovine Serum. Every three days, EB’s were allowed to gravity
settle and the medium was gently removed and replaced. RNA
and chromatin was harvested three weeks later for analysis.
Analysis of gene expression in iPS cells
iPS cells were grown without MEF feeders for preparation of
RNA to be used in gene expression analysis. Cells were seeded to
matrigel coated dishes and filtered conditioned medium from
mouse embryo fibroblasts was used for culture. RNA was purified
from cells using standard techniques and treated with DNAse to
remove residual genomic DNA from the cells. cDNA synthesis was
primed with oligo dT and reverse transcriptase. In all cases a tube
was processed in parallel without the addition of reverse
transcriptase to serve as a control for possible DNA contamina-
tion. The presence of RNA transcripts were detected using 28
thermal cycles with the primer pairs for OCT4, SOX2, hTERT,
NANOG, KLF4, cMYC, and GAPDH indicated in Table 5. RNA
was replaced with water as a negative control for the reaction.
Chromatin Immunoprecipitation
The Chromatin Immunoprecipitation (ChIP) analysis of
repressive histone modifications at the 59-region of DUX4 was
performed on primary fibroblasts, induced pluripotent stem (iPS)
cells and corresponding embryoid bodies (EB) derived from
unaffected individuals and FSHD patients, following a previously
described protocol [3,26]. Briefly, cells were cross-linked with
formaldehyde at 1.42% final concentration for 15 min at room
temperature, quenched, and sonicated to generate 500–100 bp
DNA fragments. 25 mg aliquots (representing approximately
500,000 cells) of chromatin were used for each immunoprecipi-
tation with anti-Histone H3K9me3 antibodies (Abcam) and
nonimmune IgG fraction used as a mock control. After reverse
cross-linking and DNA purification, the IP products were analyzed
by real time PCR. The 59-region of the DUX4 gene was analyzed
using the 4q-specific D4Z4 primers, 4qHox or Q-PCR, that detect
internal D4Z4 units including the last repeat unit [3]. The real-
time PCR signals obtained for IP antibodies were normalized to
mock control IgG and to input to account for the number of D4Z4
repeats. Data are presented as mean 6 stdev and represent the
results of at least three independent immunoprecipitations
followed by real-time PCR analysis done in triplicates.
Generation of antibodies to DUX4
We generated monoclonal antibodies to the amino- and
carboxy-terminus of DUX4 for this study. The full characteriza-
tion of these antibodies will be published separately [10]. Briefly,
the N-terminal 159 amino acids and the C-terminal 76 amino
acids of DUX4 were fused to glutathione-s-transferase tags,
respectively, and injected into the animals as immunogens. Mouse
monoclonals were produced at the Antibody Development core
facility at the Fred Hutchinson Cancer Research Center and will
be commercially available. Rabbit monoclonals were produced in
collaboration with and will be available through Epitomics
(Burlingame, CA). Hybridoma clones were screened for specificity
by ELISA, western blot and immunofluorescence in C2C12
myoblasts transfected with DUX4. The C-terminal antibodies
P4H2, P2B1 and E5-5 are specific to DUX4 and do not recognize
DUX4c, whereas the N-terminal antibodies P2G4 and E14-3
recognize both DUX4 and DUX4c.
Protein analysis
For western blotting, protein lysates were prepared by
resuspension in standard Laemmli buffer and sonicated briefly.
Equivalent amounts of test samples were loaded onto 4–12%
gradient gel and transferred to nitrocellulose membrane, which
were then blocked with 5% non-fat dry milk in PBS 0.1% Tween-
20. Custom monoclonal antibodies (Epitomics, Burlington, CA)
raised against DUX4 were used to probe the blots and detected by
ECL reagent (Pierce, Rockford, IL). Membranes were stripped
and reprobed with anti-a-tubulin antibody (Sigma-Aldrich, St
Louis, MO) for loading control. Immunoprecipitation was
performed on samples resuspended in PBS with protease inhibitor
cocktail (Roche) by incubating overnight at 4uC with pooled anti-
DUX4 rabbit monoclonal antibodies bound to protein A- and G-
coupled Dynabeads (Invitrogen, Carlsbad, CA). Samples were
eluted directly into Laemmli buffer and analyzed on western blot
as described. For immunofluorescence, cells were fixed in 2%
paraformaldehyde for 7 min and permeabilized in 1% Triton X-
100 in PBS for 10 min at room temperature. Cells were probed
with pairs of rabbit and mouse primary antibodies raised against
N- or C-terminus of DUX4 diluted in PBS overnight at 4uC.
Double labeling was detected with Alexa Fluor 488 goat anti-
mouse IgG and Alexa Fluor 568 goat anti-rabbit IgG (Invitrogen)
at 1:500 in PBS for 1 hr and counterstained with DAPI.
DUX4 IHC on frozen tissue
Immunohistochemistry was performed by the FHCRC Exper-
imental Histopathology Shared Resource. Six-micron sections of
OCT embedded frozen de-identified human testes tissue were
sectioned and fixed for 10 minutes in 10% neutral buffer formalin.
The slides were rehydrated in TBS-T wash buffer, permeablized
with 0.1% triton X-100 for 10 minutes, and then endogenous
peroxidase activity was blocked with 0.3% hydrogen peroxide
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50% acetone and 50% methanol was used for antigen retrieval on
a subset of slides. Protein block containing 0.25% casein and 0.1%
Tween 20 was applied for 10 minutes. Slides were incubated over
night at 4 degrees C with a 1:5 dilution of either clone E5-5 or
P2B1 in a 0.3 M NaCl antibody diluent containing 1% BSA.
Staining was developed using Mach2 HRP-labeled polymers
(Biocare Medical, Concord, CA). The staining was visualized with
3,39-diaminobenzidine (DAB, Dako, Cupertino, CA) for 8 min-
utes, and the sections were counter-stained with hematoxylin
(Dako) for 2 minutes. Concentration matched isotype control
slides were run for each tissue sample (Jackson ImmunoResearch).
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